Clinical trials: Tirzepatide
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07868354
- Testing
- Tirzepatide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Obesity
A Study to Evaluate ALN-2232 in Participants With Obesity
The purpose of this study is to: evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity evaluate the safety, tolerability…
- Trial name
- NCT07463846
- Testing
- ALN-2232, Tirzepatide
- Where
- Canada
- Volunteers
- 156 people
- Sponsor
- Alnylam Pharmaceuticals
Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with…
- Trial name
- BMT-801 (NCT06565611)
- Testing
- bremelanotide, tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Palatin Technologies, Inc
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Healthy
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT05810597
- Testing
- Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
- Trial name
- NCT03131687
- Testing
- tirzepatide, Dulaglutide
- Where
- 49 sites in United States, Poland and 2 more
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-4 (NCT03730662)
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 216 sites in United States, Argentina and 13 more
- Volunteers
- 2,002 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
- Trial name
- NCT03311724
- Testing
- Tirzepatide
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 1, Overweight, Obesity
- Trial name
- NCT07803744
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide…
- Trial name
- TOGETHER-PsA (NCT06588296)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 86 sites in United States, Puerto Rico
- Volunteers
- 279 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or…
- Conditions
- Obesity, Overweight, Overweight With One Weight Related Comorbidity
- Trial name
- GYMINDA (NCT06965413)
- Testing
- RO7204239, Tirzepatide
- Where
- 35 sites in United States, Poland and 2 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in…
- Trial name
- NCT05706506
- Testing
- Tirzepatide
- Where
- 32 sites in United States
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
- Trial name
- NCT05963022
- Testing
- Tirzepatide
- Where
- 28 sites in China
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company